NervGen Pharma Corp

NervGen Pharma Corp NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company. NVG-291 is currently in Phase 1 clinical trials in healthy volunteers.

NervGen’s lead drug candidate, NVG-291, is a first of its kind experimental drug administered by injection under the skin. NVG-291 relieves the inhibitory effects of CSPGs and thus enables nervous system repair. In animal studies, this therapeutic approach promoted nervous system repair and enhanced recovery of functions such as walking, bladder control, vision, and memory. After completing our Ph

ase 1 clinical trial, we plan to study the effectiveness and safety of NVG-291 initially in people with spinal cord injury, Alzheimer’s disease and multiple sclerosis.

*Please note*: We do not respond to messages directly through this account. If you would like to get in touch with us, please visit our website (www.nervgen.com) or email us at [email protected].

Address

112-970 Burrard Street, Unit 1290
Vancouver, BC
V6Z2R4

Website

Alerts

Be the first to know and let us send you an email when NervGen Pharma Corp posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to NervGen Pharma Corp:

Shortcuts

Share

Category